Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.
Rasmus HelgebostadMona-Elisabeth R RevheimKjersti JohnsrudKristine AmlieAbass AlaviJames Patrick ConnellyPublished in: Diagnostics (Basel, Switzerland) (2022)
Somatostatin receptor (SSTR) agonist tracers used in nuclear medicine scans are classically used for neuroendocrine tumor diagnosis and staging. SSTR are however, expressed more widely in a variety of cells as seen in the distribution of physiological tracer uptake during whole body scans. This provides opportunities for using these tracers for applications other than NETs and meningiomas. In this qualitative systematic review, novel diagnostics in SSTR-PET imaging are reviewed. A total of 70 studies comprised of 543 patients were qualitatively reviewed. Sarcoidosis, atherosclerosis and phosphaturic mesenchymal tumors represent the most studied applications currently with promising results. Other applications remain in progress where there are many case reports but a relative dearth of cohort studies. [ 18 F]FDG PET provides the main comparative method in many cases but represents a well-established general PET technique that may be difficult to replace, without prospective clinical studies.
Keyphrases
- pet imaging
- neuroendocrine tumors
- positron emission tomography
- computed tomography
- systematic review
- pet ct
- end stage renal disease
- induced apoptosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- lymph node
- bone marrow
- cardiovascular disease
- meta analyses
- magnetic resonance
- peritoneal dialysis
- contrast enhanced
- cell proliferation
- patient reported outcomes
- binding protein
- case control